Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4.
Prz Gastroenterol
; 13(1): 22-29, 2018.
Article
in En
| MEDLINE
| ID: mdl-29657607
ABSTRACT
INTRODUCTION:
Dual therapy (PegIFN and ribavirin) (DT) was the standard of care in patients infected with HCV genotype 4 (HCV-4) until 2014. Nowadays, new treatment options are available including interferon (IFN)-based and other IFN-free regimens.AIM:
To assess the efficacy (SVR24) and safety of DT and the selected predictor factors of SVR in HCV-4 infected patients. MATERIAL ANDMETHODS:
One hundred and twelve patients (62 men) of median age 23 years were treated with DT for 48/72 weeks (107/5) in the years 2006-2014. Most of them were treatment naïve (80.4%) and with fibrosis F ≤ 2 (83.1%). To select a subset of independent predictors of SVR Logistic Regression Analysis was applied.RESULTS:
SVR24 was achieved in 46/112 (41.1%) patients. The mean viral load was 5.55 log10 IU/ml. Lack of therapy experience increases the odds of achieving SVR (OR = 4.17; 1.04-16.67), whereas more advanced fibrosis and higher baseline viral load tend to decrease the probability of SVR (OR = 0.05; 0.01-0.52 and OR = 0.44; 0.17-1.13, respectively). In contrast, the weight loss is associated with higher probability of virological response (OR = 4.31; 1.37-13.60). Two hundred and seventy-nine adverse events (AEs) were reported in 96 individuals. The rates and types of AEs were similar in patients treated with PegIFN-α2a/RBV and PegIFN-α2b/RBV. Overall, 3 (2.7%) patients discontinued therapy prematurely because of serious AEs.CONCLUSIONS:
SVR24 was low. Loss of weight was a new positive predictive factor of SVR found in our study. Most of the AEs were typical of those previously reported for DT.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
Prz Gastroenterol
Year:
2018
Document type:
Article
Affiliation country:
Poland
Publication country:
PL
/
POLAND
/
POLONIA
/
POLÔNIA